Medicina anticipatoria vs medicina preventiva. Como crear enfermos buscando la salud. (I) Las Estadísticas

Antonio Zarazaga; Ángeles Franco-López; Jesús M. Culebras

doi:10.19230/jonnpr.3254

Autores/as

Antonio Zarazaga Jefe de Sección en Servicio de Cirugía General y de Urgencia del Hospital Universitario La Paz, hasta 2013. Profesor colaborador, Departamento de Cirugía, Universidad Autónoma de Madrid, España
Ángeles Franco-López Jefa de los Servicios de Radiología de los hospitales de Vinalopó y Torrevieja. AcProfesora de Universidad por ANECA, Alicante, España
Jesús M. Culebras De la Real Academia de Medicina de Valladolid y del IBIOMED, Universidad de León. Miembro de Número y de Honor de la Academia Española de Nutrición y Dietética Académico Asociado al Instituto de España. AcProfesor Titular de Cirugía. Director, Journal of Negative & No Positive Results. Director Emérito de NUTRICION HOSPITALARIA, España

DOI:

https://doi.org/10.19230/jonnpr.3254

Resumen

-

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Skrabanek, P., (1994) Anticipatory medicine. En: The death of humane medicine and the rise of coercive healthism. (pp.31-37). Suffolk. England. Social Affairs Unit (Ed.).

Keys A, Aravanis C, Blackburn H, van Buchem FSP, Buzina R, Djordjevic BS, …Toshima H.: (1993) The seven countries study. A scientific adventure in cardiovascular disease epidemiology. Kromhout D, Menotti A, and Blackburn H. (Eds.). Marjan Nijssen-Kramer, Studio RIVM, Bilthoven, The Netherlands. ISBN 90-6960-048-x

Blackburn H. (1999). On the Trail of Heart Attacks in Seven Countries. Epidemiology & Community Health School of Public Health. University of Minnesota. Doi: https://sph.umn.edu/site/docs/epi/SPH%20Seven%20Countries%20Study.pdf

Shepherd J.: (1995) The West of Scotland Coronary Prevention Study. A Trial of Cholesterol Reduction in Scottish Men. Am J Cardiol; 76:113C-117C

Diamond D, Ravnskov U. (2015) How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev. Clin. Pharmacol. 1–10. doi: 10.1586/17512433.2015.1012494

Ridker PM, Danielson E, Fonseca FA, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med;359:2195-207.

Heart Protection Study Collaborative Group: (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 highrisk individuals: a randomised controlled trial. Lancet;378: 2013–20 DOI:10.1016/S01406736(11)61125-2

Ravnskov U, Okuyama H, Sultan S.: (2017). Serious bias in 20 year follow-up study of statin trial. BMJ;359:j4906 doi: 10.1136/bmj.j4906

Wise J.: (2017) Long term study backs statins for patients with high LDL and no other risk factors BMJ;358:j4171 doi: 10.1136/bmj.j4171

Ford I, Murray H, McCowan C, Packard CJ.: (2016) Long-Term Safety and Efficacy of Lowering Low- density Lipoprotein Cholesterol With Statin Therapy. 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation;133:1073-1080. DOI: 10.1161/CIRCULATIONAHA.115.019014.

Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, … Sundberg R.: (2018) LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature, Expert Review of Clinical Pharmacology, 11:10, 959-970, DOI: 10.1080/17512433.2018.1519391

Collins R, Reith C, Emberson J, et al. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet;388: 2532–2561.

Silverman MG, Ference BA, Im K, et al. (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: systematic review and meta-analysis. JAMA;316:1289–1297

Ference BA, Ginsberg HN, Graham I, et al. (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J.38:2459–2472.

Schulz KF, Altman DG, Moher D. (CONSORT): (2010). Statement: updated guidelines for reporting parallel group randomised trials, BMJ;340:c332. doi: https://doi.org/10.1136/bmj.c332

Ravnskov U, Rosch PJ, McCully KS. (2012) The statin-low cholesterol-cancer conundrum.QJM;105:383-388

Abbasi J. (2019) New Cholesterol Guidelines Personalize Risk and Add Treatments. JAMA.; 321 (8): 731-732. doi:10.1001/jama.2018.21019

ASCVD Risk Estimator Plus. ACC. http://tools.acc.org/ASCVD-Risk-Estimators/#!/calculate/estimate/

White, L.: (1975) 'How to improve the public's health', New England Journal of Medicine, 293, pp. 113-11 A.

Skrabanek, P., (1994) Unhealthy obsession with health. En: The death of humane medicine and the rise of coercive healthism. (pp.37-41). Suffolk. England. Social Affairs Unit (Ed.).

Thomas, L. (1975). “Notes of a biology-watcher. The health-care system”, New England Journal of Medicine, 293, pp. 1245-1246.

Illich, I. (1975) Yatrogenesis Clínica. En: Némesis Médica. La expropiación de la salud. (pp.26-27) Barral (ed.)